Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 10, 2011, Pages 3217-3225

  Klubo Gwiezdzinska, Joanna ^a,b   Van Nostrand, Douglas ^a   Atkins, Frank ^a   Burman, Kenneth ^a   Jonklaas, Jacqueline ^c   Mete, Mihriye ^d   Wartofsky, Leonard ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131;

ADULT; ARTICLE; CANCER GROWTH; CLINICAL EFFECTIVENESS; DIFFERENTIATED THYROID CANCER; DOSIMETRIC PRESCRIBED ACTIVITY; DRUG DOSE COMPARISON; DRUG RESPONSE; DRUG TOLERABILITY; EMPIRIC PRESCRIBED ACTIVITY; FEMALE; HUMAN; LEUKOPENIA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOACTIVITY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; XEROSTOMIA;

AGED; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80053518694     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0494     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J, Ward E 2010 Cancer statistics 2010. CA Cancer J Clin 60:277-300
2. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1988-2005. JAMA 295:2164-2167
3. Ries LA, Eisner MP, Kosary CL 2006 SEER cancer statistics review, 1975-2000/2003. Bethesda, MD: National Cancer Institute. seer.cancer.gov/csr/ 1975-2001/
4. Chen AY, Jemal A, Ward EM 2009 Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115:3801-3807
5. Rego-Iraeta A, Pérez-Méndez LF, Mantinan B, Garcia-Mayor RV 2009 Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid cancer. Thyroid 19:333-340
6. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS 2009 Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 18:784-791
7. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
8. van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L 2002 Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 12:121-134 (Pubitemid 34218137)
9. Kulkarni K, van Nostrand D, Atkins F, Aiken M, Burman K, Wartofsky L 2006 The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid 16: 1019-1023 (Pubitemid 46141304)
10. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, Chan CY 2006 Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 47:1587-1591 (Pubitemid 47545022)
11. Benua RS, Cicale NR, Sonenberg M, Rawson RW 1962 The relation of radioiodine dosimetry to results and side effects in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 87:171-182
12. Samuel AM, Rajashekharrao B, Shah DH 1998 Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 39:1531-1536 (Pubitemid 28459881)
13. Lassmann M, Reiners C, Luster M 2010 Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer 17:R161-R172
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
15. van Nostrand D, Freitas J 2006 Side effects of 131-I for ablation and treatment of well differentiated thyroid carcinoma. In: Wartofsky L, Van Nostrand D, eds. Thyroid cancer: a comprehensive guide to clinical management. 2nd ed. Totowa, NJ: Humana Press; 459-485
16. Sgouros G, Song H, Ladenson PW, Wahl RL 2006 Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a doserate method and dosimetric implications of the 80-mCi rule. J Nucl Med 47:1977-1984 (Pubitemid 47544985)
17. Benua RS, Leeper RD 1986 A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. In: Medeiros-Neto G, Gaitan E, eds. Frontiers in thyroidology. Vol. 2. New York: Plenum Medical Book Co.; 1317-1321
18. Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, Reiners C, Luster M 2010 Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging 37: 896-903
19. Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M, EANM Dosimetry Committee 2008 EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35:1405-1412
20. Lee JJ, Chung JK, Kim SE, Kang WJ, Park do J, Lee DS, Cho BY, Lee MC 2008 Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med 22:727-734
21. Thomas SR, Maxon HR, Kereiakes JG 1976 In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 3:253-255
22. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA 2003 Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a riskadapted approach. J Nucl Med 44:451-456 (Pubitemid 39586024)
23. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C 1996 Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37: 598-605 (Pubitemid 126618447)